About   |  Speaker   |  Programme   |  Registration   |  Sponsoring


Lifescience Post Brexit


Whilst Brexit has not yielded its axe, its effects have already been witnessed on the life science sector.

The Guardian reported that UK scientists have been dropped from pan-EU projects as result of fear that the UK can no longer guarantee providing their funding quota [1]. 

This has been determined through a confidential survey the Guardian ran, asking Russel Group Universities their opinions. However, the impact is does not only pertain to academia. The Pharma Industry has allayed their fears. Back in May 2016, the Association of the British Pharmaceutical industry (ABPI) cautioned that the stakeholders affected by Brexit will ultimately be patients who may find it difficult to get incumbent smooth access to the latest therapies. At the time, this was reiterated by GSK and Eli Lilly [2]. 


CNN Money/Shutterstock.com

CNN Money/Shutterstock.com


It will be interesting to explore the perceived impact of Brexit and strategy changes in therapeutics and biotechnology from the perspective of policy-makers and experts in the field.


What are your expectations for the Lifescience and healthcare sector since the UK voted to leave the EU? 

On the contrary however, the Pharma industry has thus far suffered limited impact as the big Pharma players operate globally [3]. Furthermore GSK announced at the beginning of August 2016, an agreement with Verily Life Sciences LLC (formerly Google Life Sciences) to set up a joint venture: Galvani Bioelectronics [4]. This signifies an opposing view that perhaps, the industry may be able to ride out the storm.  

Our Panel